• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Elucidation of the mechanisms of alleviation of insulin resistance and hepatic steatosis by modulating cholesterol metabolism in myeloid cells

Research Project

  • PDF
Project/Area Number 19H03712
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 54040:Metabolism and endocrinology-related
Research InstitutionJichi Medical University

Principal Investigator

Ishibashi Shun  自治医科大学, 医学部, 客員教授 (90212919)

Project Period (FY) 2019-04-01 – 2023-03-31
Keywordsマクロファージ / 糖尿病 / インスリン抵抗性 / 脂肪肝 / コレステロール / HMG-CoA還元酵素 / 低分子G蛋白 / 肥満
Outline of Final Research Achievements

To clarify the role of Hmg-CoA reductase (Hmgcr) in macrophages in the development of insulin resistance and hepatic steatosis, we generated mice lacking Hmgcr in macrophages by crossing floxed Hmgcr mice with imce expressiong Cre recombinase under the control of lysozyme promoter (M-HmgcrKO). After feeding M-Hmgcr with high fat diet, M-HmgcrKO mice had better glucose tolerance, insurlin sensitivity and hepatic steatosis compared with wild-type mice. The number of maccropahges were significantly decreased in M-HmgcrKO mice compared with wild-tyoe mice, thereby contributing to reduced inflamation. Macrophages taken from M-HmgcrKO mice had reduced migratory activity compared with wild-type macrophages. Membrane-bound RhoA or Rac1 were increased in the macrophages from M-HmgcrKO mice compared with wild-type macrophages. We speculate that pharmacological or genetic targeting Hmgcr would be a promosing strategy to treat metabolic abnormalities in type 2 diabetes and/or obesity.

Free Research Field

内分泌代謝学

Academic Significance and Societal Importance of the Research Achievements

近年、肥満・2型糖尿病・非アルコール性脂肪肝の増加が世界的な課題になっている。肥満そのものの改善以外の方法として糖代謝や肝臓を標的にした治療法が開発され、臨床応用されている。しかし、糖代謝異常と脂肪肝の形成に共通な鍵分子を標的にした治療薬の実用化には至っていない。本研究成果は炎症細胞でもあるマクロファージが肥満・2型糖尿病・非アルコール性脂肪肝の病態形成に共通な鍵プレイヤーであり、そのHmgcrを阻害する戦略が2型糖尿病と非アルコール性脂肪肝を同時に改善させることを示唆している。今後、この基盤的知見に立脚した新規治療法の開発が期待される。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi